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ABSTRACT
Objectives: Patients with rheumatoid arthritis (RA) have
an increased cardiovascular risk, but the magnitude of this
risk is not known precisely. A study was undertaken to
investigate the associations between RA and type 2
diabetes (DM2), a well-established cardiovascular risk
factor, on the one hand, and cardiovascular disease (CVD)
on the other.
Methods: The prevalence of CVD (coronary, cerebral and
peripheral arterial disease) was determined in 353
randomly selected outpatients with RA (diagnosed
between 1989 and 2001, aged 50–75 years; the CARRE´
study) and in participants of a population-based cohort
study on diabetes and CVD (the Hoorn study). Patients
with RA with normal fasting glucose levels from the
CARRE´ study (RA, n = 294) were compared with
individuals from the Hoorn study with normal glucose
metabolism (non-diabetic, n = 258) and individuals with
DM2 (DM2, n = 194).
Results: The prevalence of CVD was 5.0% (95% CI 2.3%
to 7.7%) in the non-diabetic group, 12.4% (95% CI 7.5%
to 17.3%) in the DM2 group and 12.9% (95% CI 8.8% to
17.0%) in those with RA. With non-diabetic individuals as
the reference category, the age- and gender-adjusted
prevalence odds ratio (OR) for CVD was 2.3 (95% CI 1.1
to 4.7) for individuals with DM2 and 3.1 (95% CI 1.6 to
6.1) for those with RA. There was an attenuation of the
prevalences after adjustment for conventional cardiovas-
cular risk factors (OR 2.0 (95% CI 0.9 to 4.5) and 2.7 (95%
CI 1.2 to 5.9), respectively).
Conclusions: The prevalence of CVD in RA is increased
to an extent that is at least comparable to that of DM2.
This should have implications for primary cardiovascular
prevention strategies in RA.
Rheumatoid arthritis (RA) is a chronic inflamma-
tory joint disease of unknown aetiology affecting
approximately 1% of the general population.1 The
standardised mortality ratios are markedly raised in
RA, which seems largely attributable to cardiovas-
cular disease (CVD).2
The increased cardiovascular risk in patients
with RA could have several causes. First, the
prevalence of cardiovascular risk factors such as
dyslipidaemia, diabetes, hypertension, higher body
mass index, higher waist to hip ratio or impaired
physical fitness may be increased.3 Second, in
chronic diseases such as RA, unrelated conditions
such as cardiovascular risk factors are frequently
undertreated.4 Third, the chronic inflammatory
process in RA may increase the risk of CVD.5 6
The purpose of this study is to determine more
precisely the magnitude of cardiovascular risk
associated with RA. Better knowledge of this risk
is relevant for determining optimal primary cardi-
ovascular prevention strategies. A relevant com-
parator to RA is type 2 diabetes (DM2), which is
regarded by many as a CVD risk equivalent,
implying that preventive strategies in these
patients should be equal to those with established
CVD.7
METHODS
The CARRE´ study
‘‘CARRE´’’ is a Dutch acronym for CARdiovascular
research and RhEumatoid arthritis. The CARRE´
study is a cohort study investigating CVD and its
risk factors in patients with RA who will be
followed prospectively for at least 5 years. For the
present study the cross-sectional baseline data
were used. In 2000, a random sample of patients
with RA registered at the Jan van Breemen
Institute in Amsterdam, The Netherlands, was
drawn. Patients were eligible for participation if
they fulfilled the 1987 American College of
Rheumatology classification criteria, were diag-
nosed between 1989 and 2001, and were aged
between 50 and 75 years.8 Patients were enrolled
between January 2001 and January 2002. A total of
353 patients with RA participated. For the present
study we excluded patients with known type 1
diabetes (n = 6) or patients for whom fasting blood
samples were missing (n = 4).
The Hoorn study
The Hoorn study is a Dutch cohort study of
glucose metabolism and other cardiovascular risk
factors. In 1989 a random sample of all men and
women aged 50–75 years was drawn from the
municipal population registry office of Hoorn. A
total of 2484 individuals participated giving a
response rate of 71%. An extensive cardiovascular
investigation was performed in an age-, gender-
and glucose tolerance-stratified random subsample
of 631 participants (response rate 89%).9
RA-related data in the CARRE´ study
All patients with RA attended the outpatient clinic
at the Jan van Breemen Institute, where they were
seen by a research physician, and completed a
questionnaire recording demographic data, medical
and medication history. A physical examination
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was performed, including the 28 joint disease activity index
score (DAS-28).10 Furthermore, fasting blood samples were
taken to measure inflammatory parameters (erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP)), serological
markers (IgM-rheumatoid factor (IgM-RF), anti-cyclic citrulli-
nated peptides (anti-CCP) antibodies) and (possible) cardiovas-
cular risk factors such as lipid levels. IgM-RF and anti-CCP
antibodies were measured using in-house enzyme-linked immu-
nosorbent assays as described previously.11 In addition, to assess
the functional (disability) status, the Health Assessment
Questionnaire (HAQ) was used. The HAQ is a generic measure
used in various chronic diseases, using a self-reported patient-
orientated questionnaire.12
Assessment of diabetes and CVD in both study protocols
The diagnosis of diabetes was assessed using the 1999 World
Health Organization criteria.13 In the Hoorn study, the mean of
two oral glucose tolerance tests (OGTTs) and the mean of two
fasting plasma glucose levels were used. Cohort participants
with a mean fasting plasma glucose level ,6.1 mmol/l and a
mean OGTT ,7.8 mmol/l were classified as having normal
glucose metabolism (non-diabetic, n = 258) and those with a
fasting plasma glucose level >7.0 mmol/l, OGTT >11.1 mmol/
l, or already treated with glucose-lowering agents were classified
as type 2 diabetes (DM2, n = 194). The DM2 group consisted of
76 (35%) individuals who were already being treated with oral
antidiabetics or insulin and 127 (65%) individuals having DM2
based on two OGTTs and two fasting plasma glucose
measurements performed at baseline. The mean (SD) HBA1c
was 7.1 (1.8)% for DM2.14
In the CARRE´ study, fasting plasma glucose levels were used
and those with glucose levels ,6.1 mmol/l and not treated with
glucose-lowering agents were classified as patients having
normal fasting glucose (RA, n = 294).
In both cohorts CVD ascertainment was done according to
similar standard operation procedures and, if there was a
positive history of CVD, they qualified only when written
information from the participant’s general practitioner was
obtained.15 CVD consisted of coronary, cerebral or peripheral
arterial disease. In brief, coronary diseases were defined as a
history of myocardial infarction confirmed by a cardiologist or a
percutaneous transluminal coronary angioplasty or surgery for
ischaemic heart disease. Cerebral arterial disease was defined as
a history of a stroke or a transient ischaemic attack confirmed
by a neurologist or a carotid endarterectomy. Peripheral arterial
disease was defined as peripheral arterial reconstructive surgery,
limb amputation or an ankle brachial pressure index (ABPI)
,0.50. ABPI was obtained with the use of a hand-held Doppler,
measuring the maximum systolic pressure of either the dorsalis
pedis artery or posterior tibial artery divided by the maximum
systolic blood pressure in the brachial artery after a 5 min
resting period in a supine position in the CARRE´ study, and by
means of Doppler-assisted systolic blood pressure measurement
taken from the brachial and the three crural arteries on both
sides in the Hoorn study, as previously described.16 The lowest
ABPI of either limb was used for statistical analyses.
Cardiovascular risk factors in both study protocols
Cardiovascular risk factors assessed during physical examination
were blood pressure, body mass index and waist to hip ratio.
Height and weight were measured barefoot wearing light
clothes only. The body mass index was calculated as the ratio
of weight and squared height. Double readings of the systolic
and diastolic blood pressure were obtained on the right arm with
the subject in the sitting position after a 5 min rest. Hypertension
was defined as a systolic blood pressure .140 mm Hg and/or a
diastolic blood pressure of .90 mm Hg and/or the current use of
antihypertensive medication. The waist circumference and hip
circumference were measured at the level midway between the
lowest rib margin and the iliac crest and at the widest level over
the greater trochanters, respectively. The mean value of two
measurements was used. Measurements in both study protocols
were performed by different physicians.
For each patient, fasting blood samples were collected for
assessment of glucose, CRP, creatinine and lipid levels. Renal
function was assessed using the Cockcroft-Gault formula in ml/
min: ((140 2 age) 6 body weight/creatinine 6 71) 6 0.85 if
female). The formula is given in traditional units; to convert it
to International System units (mg/dl), creatinine is multiplied
by 88.4. Serum total cholesterol (TC) and triglyceride levels
were analysed by enzymatic techniques. Low-density lipopro-
tein (LDL) cholesterol levels were calculated by means of the
Friedewald formula (except when triglycerides were .
8.0 mmol/l) and the TC/HDLc ratio was calculated by dividing
total cholesterol levels by high-density lipoprotein (HDL)
cholesterol levels. Finally, patients were classified as never,
former or current smokers.
Statistical analyses
Characteristics of the populations of the CARRE´ and Hoorn
studies with a normal distribution were presented as means
with standard deviations or as absolute numbers with
percentages of the total. Non-normally distributed variables
were presented as medians with interquartile ranges. Baseline
characteristics of the control group were compared with
patients with DM2 and RA using the Student t test, Mann-
Whitney U test and Pearson x2 test, when appropriate.
Prevalence odds ratios (ORs) for CVD were calculated for
patients with DM2 and RA relative to non-diabetic controls.
Logistic regression analysis was done with three separate
models: (1) univariate analyses (model I); (2) age- and gender-
adjusted analyses (model II); and (3) analyses adjusting for the
following cardiovascular risk factors: systolic blood pressure,
antihypertensive agents, TC/HDL ratio, lipid-lowering drugs,
waist circumference, creatinine and smoking (model III). In
order to investigate the influence of inflammation on the risk of
CVD, CRP was separately introduced as an independent
variable. Analyses were carried out using SPSS 14.0 software
and p values ,0.05 were considered statistically significant.
RESULTS
Characteristics of patients with RA
A total of 343 patients with RA were included; 49 had either
known diabetes or fasting plasma glucose levels .6.1 mmol/l
and were therefore excluded, leaving 294 patients with RA with
normal fasting glucose levels in the study (table 1). Most of the
participants were IgM-RF positive and had erosions on the
radiographs. The mean disease duration was .7 years and
disease activity was moderate with a mean DAS-28 of almost 4.
Cardiovascular diseases
The prevalence of CVD based on a history of at least one
confirmed cardiovascular event was 5.0% (95% CI 2.3% to 7.7%)
in non-diabetic controls, 12.4% (95% CI 7.5% to 17.3%) in DM2
and 12.9% (95% CI 8.8% to 17.0%) in patients with RA (table 1).
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Compared with the non-diabetic controls, cerebral and periph-
eral arterial disease were more frequently observed in DM2, and
coronary and cerebral arterial disease more often in patients
with RA.
Cardiovascular risk factors
Table 1 summarises the cardiovascular risk factors of partici-
pants in the Hoorn and CARRE´ studies. Compared with non-
diabetic controls, patients with RA were more often female, had
a lower mean waist to hip ratio, lower total and LDL cholesterol
and higher HDL cholesterol levels. Patients with RA also had
higher rates of smoking, hypertension and use of lipid-lowering
drugs. No significant differences were observed in serum
creatinine levels, renal function, waist circumference, weight
and body mass index. CRP levels were higher in patients with
RA.
Prevalence of CVD in non-diabetic controls, DM2 and RA
Compared with non-diabetic controls, the OR for CVD was 3
times higher in the RA group and approximately 2.5 times
higher in the DM2 group (models I and II, table 2). Similar to
diabetes, adjustment for cardiovascular risk factors (systolic
blood pressure, antihypertensive agents, TC/HDL cholesterol,
lipid-lowering drugs, waist circumference, creatinine and
Table 1 Comparison of RA with DM2 and controls of the Hoorn study
Groups
Hoorn study CARRE´ study
Non-diabetic controls DM2 RA
Number 258 194 294
Demographic variables
Age (years) 63 (7) 66 (7)* 63 (7)
Female (%) 49 45 65*
Cardiovascular disease, N (%) 13 (5.0%) 24 (12.4%)* 38 (12.9%)*
Coronary artery disease, n (%) 10 (3.9%) 11 (5.7%) 23 (7.8)%*
Cerebral arterial disease, n (%) 2 (0.8%) 7 (3.6%)* 13 (4.4%)*
Peripheral arterial disease, n (%) 2 (0.8%) 10 (5.2%)* 4 (1.4%)
Cardiovascular risk factors
Systolic blood pressure (mm Hg) 133 (18) 144 (19)* 141 (20)*
Diastolic blood pressure (mm Hg) 81 (10) 83 (10)* 81 (9)
Antihypertensive drugs (%) 17 41* 24
Hypertension (%) 38 76* 57*
Creatinine (mmol/l) 92 (15) 92 (26) 88 (16)*
Cockroft-Gault (ml/min) 71 (16) 76 (18) * 74 (19)
Waist circumference (cm) 90 (10) 99 (11)* 92 (13)
Hip circumference (cm) 101 (7) 104 (8)* 104 (10)*
Waist:hip ratio 0.89 (0.08) 0.95 (0.08)* 0.88 (0.08)
Weight (kg) 74 (11) 80 (12)* 75 (14)
Height (cm) 169 (9) 167 (9) 168 (9)
BMI (kg/m2) 26 (3) 29 (4)* 26 (5)
Total cholesterol (mmol/l) 6.6 (1.2) 6.5 (1.3) 5.8 (1.1)*
HDL cholesterol (mmol/l) 1.4 (0.4) 1.1 (0.3)* 1.5 (0.5)*
LDL cholesterol (mmol/l) 4.6 (1.0) 4.3 (1.1)* 3.7 (1.0)*
Triglycerides (mmol/l) 1.5 (1.0–1.8) 2.0 (1.4–2.8)* 1.3 (1.0–1.8)
Statins (%) 1 2 11*
Smoking
Never (%) 35 39 21*
Former smoker (%) 35 36 47*
Current smoker (%) 30 25 32*
CRP (mg/l) 1 (1–3) 2 (1–4)* 6 (3–18)*
RA variables
Age at onset RA (years) 55 (8)
RA duration (years) 7 (4–10)
IgM-RF >30 IU/ml (%) 70
Anti-CCP >50 AU/ml (%) 54
Erosions on radiographs (%) 83
DAS-28 3.8 (1.4)
HAQ 0.8 (0–3)
Current methotrexate users (%) 60
Current sulfasalazine users (%) 15
Current hydroxychloroquine users (%) 7
Current prednisone users (%) 15
Current biological users (%) 10
Data presented as mean (SD), n (%) or median (interquartile range).
BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; CVD, cardiovascular disease; DAS-28, 28 joint
disease activity index score; DM2, diabetes mellitus type 2; HAQ, health assessment questionnaire; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; RA, rheumatoid arthritis; RF, rheumatoid factor.
*Variables significantly different from non-diabetic controls.
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smoking) moderately attenuated the OR in RA, but RA
remained independently associated with CVD (model III,
table 2). Adding CRP to model II resulted in a slightly decreased
ratio of RA to controls for CVD. For example, introduction of
CRP into model II reduced the OR by approximately 5%. As in
some studies an ABPI cut-off value of 0.9 is used to define
peripheral arterial disease, regression analyses were also per-
formed using this cut-off value. This resulted in age- and gender-
adjusted OR for CVD almost 2.5 times higher than controls in
DM2 and 2 times higher than controls in RA.
DISCUSSION
The risk of CVD associated with RA equals that of DM2. This
excess cardiovascular risk in comparison with the general
population is explained only partly by conventional cardiovas-
cular risk factors. Hence, RA itself should be regarded as a strong
independent cardiovascular risk factor for which cardiovascular
risk management, as in DM2, should be considered.17
In the present study we observed a 2–3-fold higher risk of
prevalent CVD in patients with RA than in non-diabetic
controls, which is similar to that in DM2. The pattern of CVD
manifestations was different, however, with a predominance of
coronary artery disease in RA as opposed to peripheral arterial
disease in DM2. The increased CVD risk in RA could be entirely
due to traditional cardiovascular risk factors, but this is
unlikely.18–20 In our patients with RA, some traditional risk
factors were increased, some decreased, and many were similar
to controls, and these findings correspond with other studies.21
Moreover, the chance of having CVD was attenuated—but still
significantly increased—after adjustment for traditional cardio-
vascular risk factors. Undertreatment of cardiovascular co-
morbidity might be another reason why patients with RA have
an increased risk of CVD.22 This is also unlikely as, for instance,
the ratio of subjects receiving antihypertensive agents and those
who qualified for antihypertensive treatment according to
national guidelines was comparable in patients with RA and
controls (data not shown).
Epidemiological, clinical and laboratory investigations have
shown that the immune system and inflammation play a major
role in all stages of atherosclerosis and contribute considerably
to the increased cardiovascular risk.23 Inflammation is known to
cause deterioration of fatty streaks into (unstable) plaques,
plaque ruptures and complement activation.24 25 Inflammation
may also act synergistically with conventional cardiovascular
risk factors in the pathogenesis of atherosclerosis. For example,
inflammation is associated with a higher systolic blood pressure
and an adverse lipid profile.26 27 Hence, it can be expected that
CVD occurs more frequently in diseases with a high inflamma-
tory burden such as RA. This is supported by observations that
disease severity is associated with an increased mortality ratio,
and that treatment with powerful anti-inflammatory drugs
such as tumour necrosis factor a (TNFa) blocking agents
reduces the cardiovascular risk in RA.28 29 However, within the
RA group as well as in the glucose-stratified participants of the
Hoorn study, we were unable to demonstrate a significant
relationship between inflammatory markers and CVD. This
might be due to a type II error, as the study was not designed to
study CVD risk at different levels of inflammation. Also, it may
be that the cumulative inflammatory burden (eg, areas under
the curve for CRP) over the last years would need to be assessed
in order to show an association between disease activity and
CVD risk in patients with RA. Indeed, in a series of 47 patients
with RA without traditional cardiovascular risk factors, no
correlation was found between the carotid intima media
thickness (cIMT) and CRP levels at the time of ultrasound.30
However, a significant association was observed between mean
CRP values and cIMT.31 The distribution of patients with RA in
four quartiles according to mean CRP values revealed statisti-
cally significant differences in the cIMT. Moreover, patients
with the highest mean CRP values (.15 mg/l) had a greater
cIMT than the remaining patients.
Non-steroidal anti-inflammatory drugs (NSAIDs), cyclo-
oxygenase-2 (COX-2) inhibitors and disease-modifying anti-
rheumatic drugs (DMARDs) are other drugs that influence the
cardiovascular risk in patients with RA. Indeed, it was shown
that the use of DMARDs was associated with a lower
cardiovascular risk mediated by inflammation suppression.32
The net effects of NSAIDs and COX-2 inhibitors on cardio-
vascular risk are more difficult to ascertain as, on the one hand,
most (but not all) have prothrombotic effects and, on the other
hand, these agents improve inflammation and mobility of
patients with RA, which might counterbalance the pro-
thrombotic effects.33
RA and diabetes may share several mechanisms that
contribute to the increased risk of CVD, and the presence of
chronic inflammation implicated in the pathogenesis of RA,
diabetes and atherosclerosis appears to be the key feature.34 35
TNFa, a pivotal proinflammatory cytokine in RA, arises from
adipose tissue and during chronic hyperglycaemia in DM2 and
has harmful effects on the pathway of insulin signalling.36 TNFa
may also cause insulin resistance through its ability to decrease
the tyrosine kinase activity of the insulin receptor.37 In addition,
TNFa impedes the insulin-mediated disposal of glucose in the
skeletal muscle.38 Interestingly, TNFa blockade has been shown
to yield a rapid dramatic improvement in insulin resistance in
RA.39 40 This improvement in insulin resistance following anti-
TNFa therapy has been found to yield better glycaemic control
in patients with RA with concomitant diabetes.41 Glucose
intolerance, present in RA and diabetes, is another parallel, and
there is a direct correlation between the degree of impaired
glucose handling and inflammation.42 Moreover, RA and
diabetes associate with an adverse cardiovascular risk profile,
particularly dyslipidaemia.43 44
Our study has several limitations. First, causality can only be
investigated to a limited extent in cross-sectional epidemiological
Table 2 Prevalence odds ratios (ORs) for cardiovascular disease using
controls as a reference
OR (95% CI) p Value
Model I
Non-diabetic controls 1.00 (reference)
DM2 2.62 (1.29 to 5.32) 0.008
RA 2.81 (1.46 to 5.42) 0.002
Model II
Non-diabetic controls 1.00 (reference)
DM2 2.31 (1.13 to 4.72) 0.022
RA 3.11 (1.59 to 6.08) 0.001
Model III
Non-diabetic controls 1.00 (reference)
DM2 2.01 (0.90 to 4.51) 0.090
RA 2.70 (1.24 to 5.86) 0.012
DM2, diabetes mellitus type 2; RA, rheumatoid arthritis.
Model I, crude associations.
Model II, corrected for age and gender.
Model III, corrected for cardiovascular risk factors (age and gender, systolic blood
pressure, antihypertensive agents, total cholesterol/high-density lipoprotein
cholesterol (TC/HDL) ratio, lipid-lowering drugs, waist circumference, creatinine and
smoking).
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studies. Second, there may be differences between the Hoorn
study and the CARRE´ study as cardiovascular risk measurements
were performed by different physicians and some by different
techniques. In particular, the different definition of diabetes in the
two studies is important. In the Hoorn study, controls and DM2
were classified according to the mean of two fasting plasma
glucose levels and the mean of two OGTTs, whereas one single
fasting plasma glucose level was used in the CARRE´ study. Hence,
the number of true non-diabetic patients in the RA group might
actually be lower. Such non-exclusion of diabetic patients would
inflate the OR for RA. When, however, participants of the Hoorn
study were stratified according to fasting plasma glucose levels
alone, the age- and gender-matched ORs for RA slightly decreased
but remained more than twofold increased compared with
controls in the Hoorn study (data not shown). A significant
underestimation of diabetes in RA is therefore not likely. Finally,
the Hoorn study was conducted about a decade earlier than the
CARRE´ study. Hospital admission rates for CVD showed a
marked decline during the second half of the 1990s in The
Netherlands, which indicates that the prevalence of CVD in the
CARRE´ study relative to the prevalence of CVD in the controls
assessed one decade earlier is probably more underestimated than
overestimated.45 In addition, differences in HDL-cholesterol levels
between the two cohorts are difficult to interpret as HDL-
cholesterol levels may have drifted up over time.
In conclusion, the prevalence of CVD in RA is greatly
increased compared with healthy individuals and is comparable
to that in DM2. A higher prevalence of traditional cardio-
vascular risk factors only partly explains this increased risk of
CVD in RA. Hence, RA should be considered a high-risk
condition for CVD, potentially equivalent to that in DM2,
emphasising the need for cardiovascular risk management in
RA. Future well-controlled prospective studies including
patients with RA and DM2 at baseline would be helpful to
confirm and extend our findings.
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